News | Mobile Devices | June 13, 2018

Medisafe Demonstrates Double-Digit Impact on Hypertension Medication Adherence

Use of medication management mobile app increased prescription refill rates by almost 10 percent

Medisafe Demonstrates Double-Digit Impact on Hypertension Medication Adherence

June 13, 2018 — Medication management platform Medisafe released data showing that, on average, hypertensive patients increase their prescription refills by almost 10 percent after they start using the company's mobile app.

In order to determine the increase in prescription claims, the study matched Medisafe users to their refill data using a HIPAA-compliant, non-identification process. The investigators calculated a medication possession ratio ("MPR") for each of the over 4,000 patients taking an antihypertensive medication pre-app (before the patient started using Medisafe) and on-app (once the patient started using Medisafe) and grouped them into corresponding MPR deciles (0 - 0.1 being the least adherent, 0.9 - 1.0 being the most adherent). MPR is a standard metric used by the healthcare industry to track medication adherence, in which an MPR of 1.0 corresponds to a 100 percent refill rate.  

Key findings include:

  • Of patients not in the top MPR decile pre-app, 82 percent (1,371 of 1,667) increased by at least one decile on-app;
  • Of patients with a pre-app MPR < 0.8, 78 percent (920 of 1,179) increased by at least 2 deciles;
  • Of patients with a pre-app MPR < 0.5, 74 percent of patients (320 of 431) increased by at least 5 deciles; and
  • The proportion of patients with MPR ≥ 0.80 increased from 70.8 percent pre-app to 86.25 percent on-app, a 21.8 percent relative increase.

 

Summary Table

Adherence (MPR) Pre-app On-app p-value % change
Mean 0.84 0.92 <.0001 9.52%
Standard deviation 0.23 0.13    
Adherent [MPR ≥ 0.80] 2858 (71%) 3482 (86%) <.0001 21.13%

N= 4,037

 

The hypertension results follow data released from the same landmark study in early March on the accuracy of Medisafe's patient reported adherence data. In the coming months, Medisafe will continue to release results, including data regarding the platform's impact on adherence and persistence across other therapeutic areas.

For more information: www.medisafe.com


Related Content

News | Cardiovascular Clinical Studies

November 29, 2023 — Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

Home November 29, 2023
Home
News | Cardiovascular Clinical Studies

November 29, 2023 — Foldax, Inc., a leader in the development of innovative, polymer heart valves, today announced ...

Home November 29, 2023
Home
News | Cardiovascular Clinical Studies

November 28, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announces the first patient in the world has been ...

Home November 28, 2023
Home
News | Cardiovascular Clinical Studies

November 27, 2023 — Esperion announced the presentation of results from a pre-specified, exploratory analysis of CLEAR ...

Home November 27, 2023
Home
News | Cardiovascular Clinical Studies

November 22, 2023 — The first clinical trial to challenge the routine implantation of a defibrillator in myocardial ...

Home November 22, 2023
Home
News | Cardiovascular Clinical Studies

November 15, 2023 — Researchers at the University of Leicester have discovered the mechanism by which cholesterol in our ...

Home November 15, 2023
Home
News | Cardiovascular Clinical Studies

November 6, 2023 — Bristol Myers Squibb announced that research across the company’s cardiovascular franchise will be ...

Home November 06, 2023
Home
News | Cardiovascular Clinical Studies

October 20, 2023 — JenaValve Technology, Inc., developer and manufacturer of the Trilogy Transcatheter Heart Valve (THV) ...

Home October 20, 2023
Home
News | Cardiovascular Clinical Studies

October 12, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home October 12, 2023
Home
Subscribe Now